Provides R&D project management for Business Development transactions, from early diligence through governance, deal execution and integration into business as usual. Acts as a strategic partner to BD, Alliance Management and R&D stakeholders, leading cross-functional planning, risk management and governance readiness across multiple therapeutic areas and development phases.
Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining patient segmentation and decision criteria within Clinical Matrix Teams. Validates predictive, pharmacodynamic and resistance biomarkers using platforms such as NGS, ctDNA, flow cytometry and multi-omic analyses to inform dose selection and go/no-go decisions.
Lead in vitro and cellular pharmacology strategy for small-molecule drug design programs, defining screening cascades and guiding biophysical, biochemical and cell-based assays from hit identification to candidate selection. Bridge computational AI/ML predictions with laboratory validation, managing CRO partnerships and collaborating with chemistry, structural biology and translational teams.
Designs and implements translational strategies for small molecule oncology and immunology programs, from early discovery through candidate selection and clinical phase. Oversees CRO activities, PK/PD and safety assessments, and biomarker strategies, bridging computational predictions with laboratory validation. Some roles include managing 2-3 in vivo pharmacologists.
Leads the design and execution of real-world evidence and health outcomes studies across oncology assets, managing timelines, budgets and vendor deliverables. Reviews protocols, analysis plans and publications, and advises medical, market access and commercial teams on payer and HTA evidence needs. Builds relationships with external experts and maintains knowledge of real-world data sources.
Leads the design and execution of real-world evidence and health outcomes studies for oncology assets, managing timelines, budgets and quality of protocols, analyses and publications. Advises internal medical, market access and commercial teams and external experts on evidence strategy for HTA submissions, reimbursement and value-based pricing. Requires deep knowledge of RWD sources and payer evidence needs.
Drives an AI-native strategy for clinical operations, framing hypotheses and building working agentic AI prototypes hands-on before scaling them into production with enterprise technology teams. Combines strategy, solution architecture and build-buy-partner decisions, including vendor evaluation, business cases and GxP-validated deployment, working with R&D leaders and frontline users.
Senior physician leader providing medical oversight, safety monitoring and clinical insight across lung cancer studies, from protocol design through data interpretation. Serves on the Clinical Matrix Team, contributes to regulatory interactions and external scientific engagement, and mentors Medical Directors within the programme. Requires deep lung cancer drug development expertise, including early phase trials.
Serves as the physician within oncology clinical programme teams for lung and head/neck cancers, leading medical monitoring, safety oversight and clinical data interpretation across Phase I–III studies. Partners with a Senior Scientist and cross-functional matrix teams on protocol development, regulatory interactions and investigator engagement, with on-site presence 2–3 days per week.
Leads clinical development of GU oncology assets, designing and executing Phase 1-3 interventional trials and serving as a core member of the Clinical Matrix Team. Provides real-time medical monitoring, safety data review with pharmacovigilance, and authors clinical study reports and regulatory responses. Builds key external expert relationships and contributes to business development diligence.
Owns the clinical strategy, scientific narrative and benefit-risk framework for a genitourinary oncology asset, acting as the senior clinical authority on the Medicine Development Team core quad. Sets asset-level evidence-generation and governance strategy while study-level delivery is led by Senior Scientists, and represents Clinical Development in health authority interactions, advisory boards and alliance partnerships. Also mentors clinical development talent and applies AI-enabled analytics to sharpen development decisions.
Serves as the physician within a clinical program team, leading medical monitoring and safety oversight for genitourinary oncology studies. Interprets clinical and safety data, contributes to protocol development and regulatory interactions, and acts as a core member of the Clinical Matrix Team. May guide other physicians on complex multi-study programs.
Provides clinical and scientific leadership across translational and clinical studies within GSK's Respiratory, Immunology & Inflammation Research Unit, focusing on aging. Leads the Clinical Matrix Team, designs clinical development plans and protocols, oversees medical monitoring and safety, and drives regulatory interactions. Works cross-functionally with biology, regulatory, commercial and statistics to advance assets from early development.
Serves as the physician within an oncology clinical programme team, leading medical monitoring and safety oversight for GI cancer studies. Interprets clinical and safety data, contributes to protocol development, and engages investigators, KEEs and health authorities. A core member of the Clinical Matrix Team, providing medical guidance within a matrixed pharma R&D environment.
Senior physician leader providing medical oversight, safety monitoring and clinical data interpretation across sarcoma oncology studies, from protocol design through regulatory interactions. Serves as a senior member of the Clinical Matrix Team, mentoring Medical Directors and engaging external experts, advisory boards and health authorities.
